To evaluate the efficacy of MK-7240 compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12
A phase three study to evaluate the safety and tolerability of MK-7240 for patients who have moderate to severely active ulcerative colitis (UC).
UC as defined by Modified May Score of 5-9, Endoscopic sub-score greater than or equal to 2 Has inadequate response or LOR to 1 more prior UC therapy.
Principal Investigator